Could Glow-in-the-Dark Tobacco Plants Light Up the Living Rooms of the Future?
By Kristin Hohenadel,
Slate
| 01. 15. 2014
Glowing plants - as seen in the seemingly fantastical flora of the 2009 film Avatar - are no longer just a special effect. Molecular biologist Alexander Krichevsky, of St Louis biotech company Bioglow, has developed the Starlight Avatar, a genetically modified tobacco plant that glows in the dark, as a first step towards a world in which our highways and homes might be illuminated not with electricity but with the luminescent glow of plant life. … Bioglow is holding an online auction of 20 Starlight Avatar plants for those in the US who are curious about seeing the luminescent wonders for themselves.
''There are no naturally occurring glowing/bioluminescent plants in nature,'' Krichevsky says. ''While there are a number of various glowing species - fireflies, glow worms, glowing fish etc, there are no glowing plants. Starlight Avatar is the first one.''
He says that ostensibly ''bioluminescent'' plants have existed for about 20 years, mostly for research purposes.
''These plants, however, needed to be sprayed with chemicals to achieve a temporary and very weak glowing effect, or be illuminated by UV lights,''...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...